Charles River二季度恢复有机增长并上调全年指引但盘中已大涨

SpaceX tumble amid AI spending concerns; Musk outlines $1 trillion revenue target
Introduction & Market Context
Charles River Laboratories International (NYSE:CRL) presented its second-quarter 2026 results on August 5, 2026, marking a significant inflection point for the contract research organization. The company achieved organic revenue growth of 0.1% for the first time since the third quarter of 2023, while exceeding its prior outlook and raising full-year guidance. Shares surged 11.64% to $261.37, approaching the 52-week high of $267.99, as investors responded positively to improving demand trends and margin expansion prospects.
The presentation revealed that both revenue and non-GAAP earnings per share exceeded prior expectations, with EPS of $3.02 representing a 47% sequential increase versus the first quarter and beating analyst estimates of $2.74. The company’s recovery appears to be gaining traction as biopharma demand trends strengthen across both global pharmaceutical clients and better-funded biotech companies.
Quarterly Performance Highlights
Charles River’s second-quarter results demonstrated meaningful progress across multiple metrics. As shown in the following consolidated financial performance summary, the company generated $1,004.1 million in revenue, representing a 2.7% reported decline but a 0.1% organic increase when adjusted for acquisitions, divestitures, and foreign currency impacts.
The non-GAAP operating margin reached 20.5%, up 420 basis points sequentially from the first quarter, though down 160 basis points year-over-year. This sequential improvement was largely driven by the partial-quarter benefit from recent divestitures and reduced pressure from discrete margin headwinds. Manufacturing’s non-GAAP operating margin jumped to 37.8% from 25.9% in the first quarter, primarily benefiting from the CDMO divestiture.
Non-GAAP EPS of $3.02 exceeded the prior outlook, with over half of the outperformance driven by better-than-expected top-line results. A net investment gain associated with the deferred compensation plan benefited EPS by $0.19 in the quarter, partially offset by a $0.07 headwind from a higher-than-expected tax rate.
The following slide highlights the key achievements for the quarter:
Discovery and Safety Assessment Segment Shows Momentum
The Discovery and Safety Assessment (DSA) segment, Charles River’s largest business, showed encouraging signs of recovery. Revenue of $606.5 million declined 1.9% on a reported basis but increased 0.2% organically, driven by higher study volume for regulated safety assessment services.
The improvement was broadly distributed across multiple study types and modalities, including a discernible increase in IND-enabling studies as clients shift research focus earlier to replenish pipelines. The company also noted continued strength in non-human primate (NHP)-related studies, reflecting clients’ focus on complex biologics. NHP-related safety assessment studies have become a competitive advantage following acquisitions of suppliers in Cambodia and Mauritius, providing more reliable internal supply.
The most compelling indicator of strengthening demand came from DSA’s booking trends. As illustrated in the following demand metrics, the DSA net book-to-bill ratio increased to 1.19x in the second quarter, up from 1.04x in the first quarter and representing the highest level in nearly four years.
Net bookings increased 12.6% sequentially to $701 million, showing broad-based improvement across both global biopharmaceutical and small and mid-sized biotech client segments. Quarter-end backlog reached $1.97 billion, up from $1.92 billion in the first quarter. This marks the third consecutive quarter with a book-to-bill ratio above 1.0x, suggesting sustainable improvement in the biopharma demand environment.
Mixed Performance Across Other Segments
The Research Models and Services (RMS) segment generated $209.5 million in revenue, down 1.4% organically. Most of the pressure came from small models in North America, primarily due to constrained spending from academic and government accounts facing flat NIH budgets and slower grant processing. However, robust demand for small models in China from mid-tier biotech and CRO clients partially offset the North American weakness.
The Manufacturing segment delivered $188.1 million in revenue, up 1.3% organically, though down 6.3% on a reported basis due to the CDMO divestiture. As shown in the following segment performance breakdown, Manufacturing achieved a 37.8% non-GAAP operating margin, representing a 500 basis point improvement year-over-year.
Microbial Solutions achieved high-single-digit organic revenue growth, driven by increased demand across three major geographic regions for endotoxin testing reagents, including Endosafe PTS rapid testing cartridges. The CDMO business reduced the segment’s organic revenue growth rate by nearly 400 basis points before being divested. Excluding the CDMO impact, Manufacturing revenue would have increased at a mid-single-digit rate organically.
Strategic Initiatives Drive Long-Term Value
Charles River continued executing on its "Pathway to Purpose" strategy during the quarter, focusing on modernization, portfolio optimization, and client-centric approaches. The company introduced an enhanced digital pathology solution in May, utilizing AI-enabled, end-to-end workflows designed to improve study turnaround times and increase pathologists’ efficiency. This solution is expected to cut at least one week from standard pathology timelines for over 140 trained pathologists.
The company completed divestitures of certain European Discovery Services sites as well as the CDMO and Cell Solutions businesses in May, refining its portfolio to focus on core competencies in regulated testing solutions. These strategic transactions were a primary driver of the 420 basis point sequential improvement in non-GAAP operating margin.
Charles River also embarked on five global lab science expansions to add bioanalysis lab capacity, supporting growing demand for large-molecule bioanalysis, biomarkers, and additional testing in both preclinical and clinical development phases. These expansions include one at Heriot Watt University’s Research Park in Scotland.
On the collaboration front, the company announced a partnership with Eli Lilly’s TuneLab AI/ML drug discovery platform in June, providing non-clinical testing expertise to help build and optimize the model. In July, Charles River announced a collaboration with Arovella Therapeutics to provide next-generation sequencing services, leveraging capabilities acquired through the recent PathoQuest acquisition.
Raised Guidance Reflects Improving Outlook
Based on second-quarter outperformance and strengthening demand trends, Charles River raised its full-year 2026 guidance across multiple metrics. The following table illustrates the updated outlook:
The company now expects organic revenue growth of 0.0% to 1.0%, up from the prior outlook of -1.5% to -0.5% decline, representing a 150 basis point improvement at the midpoint. Non-GAAP EPS guidance increased to $11.15-$11.45 from $10.80-$11.30, a $0.25 increase at the midpoint. Free cash flow guidance rose to $400-$420 million from $375-$400 million.
Management indicated the guidance increase is driven by expected operational outperformance in 2026, including in the second quarter, primarily due to improving DSA demand trends and better-than-expected Manufacturing performance. The company expects approximately 120-150 basis points of non-GAAP operating margin expansion for the full year.
For the second half of 2026, Charles River provided a detailed bridge showing expected operating margin improvement of more than 500 basis points compared to the first half:
Approximately half of the second-half improvement will be attributable to portfolio actions, including the full benefit of divestitures and lower NHP sourcing costs from the Cambodia acquisition, which will largely benefit the fourth quarter. Lower unallocated corporate costs are expected to drive approximately 150 basis points of improvement, reflecting favorable stock compensation expense versus the first half related to the CEO transition and lower fringe and employee benefit costs.
Third-Quarter Outlook and Market Reaction
For the third quarter of 2026, Charles River expects reported revenue to decline 6.0% to 4.0% year-over-year, primarily reflecting the impact of completed divestitures, while organic revenue is projected to grow 1.0% to 3.0%. Non-GAAP EPS is expected to range from $2.90 to $3.00, representing approximately 20% year-over-year growth despite a higher tax rate outlook creating a $0.10 EPS headwind.
The market responded enthusiastically to the presentation, with shares jumping 12.34% to $263 in premarket trading following the earnings announcement, before settling at $261.37, still up 11.64% from the previous close of $234.12. The stock traded within 1.9% of its 52-week high, reflecting investor optimism about the company’s recovery trajectory and margin expansion potential.
CEO Birgit Girshick emphasized the company’s positioning for improved growth: "We firmly believe these trends positioned us well to drive higher organic growth during the second half of the year." CFO Glenn Coleman highlighted the margin recovery, noting the company has "a clear line of sight into the second half improvement of at least 500 basis points compared to the first half of the year."
The return to organic revenue growth after nearly three years of decline, combined with strengthening DSA bookings, improving biotech funding environment, and strategic portfolio actions, suggests Charles River may be entering a sustained recovery phase. However, challenges remain, including continued weakness in the RMS segment from academic and government clients, potential tax headwinds from proposed legislation changes, and the need to demonstrate sustained organic growth momentum in coming quarters.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.